IL6 and COVID-19: Several major randomized trials evaluating the use of interleukin (IL)-6 inhibitors or Janus kinase (JAK) inhibitors with or without corticosteroids in patients with COVID-19 suggest that adding a second immunomodulatory drug such as baricitinib or tocilizumab to dexamethasone provides clinical benefit in patients requiring oxygen supplementation [33,34].